Actelion (Actelion) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Actelion's cash to debt ratio for the quarter that ended in Mar. 2017 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Actelion could pay off its debt using the cash in hand for the quarter that ended in Mar. 2017.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Actelion's Cash-to-Debt or its related term are showing as below:

ALIOF's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Actelion Cash-to-Debt Historical Data

The historical data trend for Actelion's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Actelion Cash-to-Debt Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Cash-to-Debt

Get a 7-Day Free Trial

4.77

3.73

5.12

No Debt

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Actelion's Cash-to-Debt

For the Biotechnology subindustry, Actelion's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actelion's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Actelion's Cash-to-Debt falls into.

Actelion Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Actelion's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Actelion had no debt ⁽¹⁾.

Actelion's Cash to Debt Ratio for the quarter that ended in Mar. 2017 is calculated as:

Actelion had no debt ⁽¹⁾.

Actelion (OTCPK:ALIOF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Actelion Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Actelion's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.